299177-89-2

Upstream product

• 211945-49-2 (R)-2-t-butyldimethylsilyloxymethyl-1-trimethylsilyloxycyclohexene 
• 145386-69-2 6-[(tert-butyldimethylsilyloxy)methyl]-1-trimethylsilyloxy-1-cyclohexene 
• 211945-47-0 (1R,2R)-2-t-butyldimethylsilyloxymethylcyclohexanol 
• 211945-48-1 (R)-2-t-butyldimethylsilyloxymethylcyclohexanone 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 86978-81-6 (3R,4R)-4-acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-1-trimethylsilyl-2-azetidinone 
• 1655-06-7 cis-ethyl 2-hydroxy-cyclohexanoate 
• 187263-73-6 ethyl (1S,2R)-2-acetoxycyclohexanecarboxylate 
• 51606-50-9 (1R,2R)-2-(hydroxymethyl)cyclohexanol 
• 74503-07-4 allyl oxalyl chloride 
• 135297-29-9 (3S,4R)-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[(2'R,6'R)-2'-(t-butyldimethylsilyloxymethyl)cyclohexanone-6'-yl]azetidin-2-one 

Relevant academic research and scientific papers

Stereoselective synthesis of novel anti-MRSA tricyclic carbapenems (trinems)

(4S)-Hydroxymethyltrinem 3 was prepared via stereoselective aldol-type reaction with optically pure (R)-2-t-butyldimethylsilyloxymethylcyclohexanone ((R)-16). (4S)-Hydroxymethyltrinem 3 was converted into various kinds of trinem derivatives with anti-MRSA activity by using the Mitsunobu reaction. (C) 2000 Elsevier Science Ltd.